# Efficacy and Safety of TAF for 48 Weeks in HBeAg Positive CHB Patients

> **NCT04864366** · — · UNKNOWN · sponsor: **Huashan Hospital** · enrollment: 150 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Tenofovir Alafenamide 25 MG [Vemlidy]

## Key facts

- **NCT ID:** NCT04864366
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-30
- **Primary completion:** 2023-10-27
- **Final completion:** 2023-12-31
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2023-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04864366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04864366, "Efficacy and Safety of TAF for 48 Weeks in HBeAg Positive CHB Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04864366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*